Knight Therapeutics | GUD - 应收帐款人

金融业

CAD

CAD 1.05B

现金及等价物

CAD 76.45M

CAD 82.22M

CAD 394.84M

CAD 165.26M

CAD 77.91M

CAD 6.21M

CAD 24.45M

698

EPS每股收益

CAD 0.13

股本和储备

CAD 767.27M

CAD 64.72M

债务利息支出

CAD 3.92M

CAD 2.46M

CAD 57.78M

CAD 953.02M

CAD -3.79M

CAD 126.9M

CAD 6.21M

普通股股本

CAD 99.68M

257.34

CAD -1.92M

CAD 133.11M

销售和管理费用

CAD 35.45M

CAD 95.4M

贸易债权人

CAD 125.76M

应收帐款人

CAD 183M

	应收帐款人	更改		日
Acasti Pharma	USD 20K		0	2025-09
Akebia Therapeutics	USD 47.03M		19.19M	2025-12
Alaunos Therapeutics	USD 2K		0	2025-06
Aurora Cannabis	CAD 48.26M		1.53M	2025-12
Avita Medical	AUD 9.11M		2.26M	2025-12
Canopy Growth	CAD 140.42M		113.56M	2025-12
Cronos Group	USD 73.17M		4.87M	2026-03
Dianthus Therapeutics	USD 52K		4.95M	2025-12
Ionis Pharmaceuticals	USD 74M		8M	2026-03
IQVIA Holdings	USD 3.38B		52M	2026-03
Knight Therapeutics	CAD 183M		7.46M	2025-12
Moderna	USD 71M		113M	2026-03
Omeros	USD 8.08M		440K	2024-06
Organigram Holdings	CAD 49.94M		14.92M	2025-12
Organon & Co	USD 1.33B		153M	2025-12
Revvity	USD 691.38M		53.29M	2026-03
Tectonic Therapeutic	USD 0		270K	2023-12
Tilray	USD 109.07M		2M	2025-09
Viatris	USD 3.08B		45M	2026-03
Xeris Pharmaceuticals	USD 51.05M		2.7M	2025-12